Research has shown that care provided through teledermatology is comparable to that delivered in face-to-face appointments, and future dermatologists are being taught to deliver care this way to improve patient access to expert dermatological care, said Nellie Konnikov, MD, professor and chief of dermatology at the Boston Department of Veterans Affairs.
Research has shown that care provided through teledermatology is comparable to that delivered in face-to-face appointments, and future dermatologists are being taught to deliver care this way to improve patient access to expert dermatological care, said Nellie Konnikov, MD, professor and chief of dermatology at the Boston Department of Veterans Affairs (VA).
Transcript (modified)
Is there any research on how the outcomes of teledermatology compare with those of face-to-face appointments?
Over the last 7 to 10 years, there are plenty of publications proving that it is effective methods of delivering dermatologic care ot our veterans. Research came from different VAs; for example, Milwaukee VA and Providence VA, especially, with satisfaction among patients and among doctors very high and comparable to care with face to face dermatology.
How would you like to see teledermatology evolve and improve?
Teledermatology is the part of the armamentarium within the whole healthcare delivery system. Right now we teach future dermatologists, residents in dermatology, to provide this type of care. And I think it will compliment any healthcare system in terms of access to expert dermatological care, and cost effectiveness of it.
What are some of the main barriers to implementing teledermatology?
The barrier could be the acceptance among primary care physicians because it's not how good the advice is, or how correct the diagnosis is, it's only if we have nurse practitioners, physicians assistants, or primary care physicians to follow our management advice, and to follow up with patients with skin disorders.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More